Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com
DuoBody®-CD3x5T4 Induces Efficient T-cell Activation, Tumor Cell Killing in HNSCC Cell Lines
November 12th 2021The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.
Read More
First-in-class Anti-CD47 Fusion Protein DSP107 Under Investigation in AML and MDS
November 10th 2021The FDA cleared an investigational new drug application for a phase 1b clinical trial examining DSP107, a first-in-class anti-CD47 fusion protein, in patients with acute myeloid leukemia and myelodysplastic syndrome.
Read More
Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC
November 8th 2021Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.
Read More
Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care
November 5th 2021Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.
Read More
Varying Pathological Features Needed to Determine Prognosis in Myoepithelial Tumors
November 2nd 2021There is significant clinical, pathological, and outcome heterogeneity in myoepithelial tumors and prognoses for these tumors cannot be determined by a single pathological feature, but rather, several patient and tumor characteristics.
Read More
Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma
November 1st 2021The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.
Read More
Children With Cancer At Higher Risk for Severe Illness from COVID-19
October 24th 2021Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness and deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from COVID-19.
Read More
Non-Hispanic Black women are approximately 40% more like to require a visit to the emergency department after breast cancer surgery, and Hispanic women are 11% more likely compared with non-Hispanic White women, according to results from a population-based study published in Breast Cancer Research and Treatment.
Read More
UGN-102 May Provide Alternative to Repetitive Surgery in Low-Grade Intermediate-Risk NMIBC
October 19th 2021Non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 produced significant, durable responses in those with low-grade intermediate-risk non–muscle invasive bladder cancer.
Read More
Because the combination of pembrolizumab, lenvatinib, and platinum-based chemotherapy showed early evidence of antitumor activity with a manageable safety profile in previously untreated patients with metastatic nonsquamous non–small cell lung cancer examined in part 1 of the phase 3 LEAP-006 trial, the second part of the research has officially begun enrollment.
Read More
Trastuzumab Duocarmazine Produces PFS Benefit in Pretreated HER2+ Breast Cancer
October 12th 2021Vic-trastuzumab duocarmazine markedly improved progression-free survival vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received 2 prior treatment regimens or ado-trastuzumab emtansine in the metastatic setting, according to data from the phase 3 TULIP trial.
Read More
Nivolumab/Cabozantinib Continues to Showcase Deep, Durable Responses in Advanced RCC
October 11th 2021Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.
Read More
Reiss Shares Secrets Behind Optimal Molecular Testing Approaches in NSCLC
October 6th 2021Pivotal trials, such as the phase 3 FLAURA trial with osimertinib in patients with EGFR-mutant non–small cell lung cancer NSCLC, have demonstrated the significant benefit yielded with targeted therapies.
Read More
Vimseltinib Demonstrates Encouraging Preliminary Efficacy, Tolerability in TGCT
October 6th 2021Vimseltinib was well tolerated and demonstrated promising preliminary efficacy in patients with tenosynovial giant cell tumors whose tumors are not amendable to surgical resection, according to results from a phase 1/2 study.
Read More
Plinabulin/Docetaxel Demonstrates Durable Antitumor Benefit in EGFR Wild-Type NSCLC
October 6th 2021The addition of plinabulin to docetaxel demonstrated durable anticancer benefit in terms of overall survival when used in the second- or third-line treatment of patients with EGFR wild-type non–small cell lung cancer who had progressed on a prior platinum-based regimen.
Read More
Triplet Combo Produces Promising Preliminary Activity in BRAF V600E–Mutant Metastatic CRC
October 5th 2021The triplet combination comprised of encorafenib, binimetinib, and cetuximab elicited encouraging responses with a manageable safety profile in patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer, meeting the primary end point of the phase 2 ANCHOR-CRC trial.
Read More
Sacituzumab Govitecan Significantly Improves HRQoL Vs Physician’s Choice in mTNBC
October 5th 2021Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.
Read More
Addition of Olaparib to Abiraterone Improves rPFS in mCRPC
September 24th 2021Olaparib in combination with abiraterone acetate demonstrated a significant and clinically meaningful improvement in radiographic progression-free survival vs abiraterone alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.
Read More
Durvalumab Plus Chemotherapy Showcases Sustained OS Benefit in ES-SCLC
September 21st 2021The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.
Read More
Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer
September 21st 2021Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.
Read More
The combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone in the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results from the phase 3 MONALEESA-2 trial.
Read More